Drugs / REP 2139
REP 2139
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02646189 | Aug 2011 → Aug 2013 | chronic hepatitis B virus infection | Replicor Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02565719 | Mar 2016 → May 2019 | chronic hepatitis B virus infection | Replicor Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02726789 | Oct 2012 → Sep 2016 | chronic hepatitis B virus infection | Replicor Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REP 2139 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02726789 ↗ |
| Known as | REP 2139-Ca | “the NAP REP 9AC' (REP 2139, given as a calcium chelate complex [REP 2139-Ca])” NCT02726789 ↗ |
| Known as | REP 2139-Mg | “REP 2139-Mg = magnesium chelate complex of REP 2139” NCT02565719 ↗ |
| Known as | REP 9AC' | “REP 9AC' (REP 2139) is a modified version of its predecessor, REP 9AC (REP 2055).” NCT02646189 ↗1“the NAP REP 9AC' (REP 2139, given as a calcium chelate complex [REP 2139-Ca])” NCT02726789 ↗ |
| Action | Inhibit | “Nucleic acid polymers (NAPs; REP 2139-Ca and REP 2139-Mg) are new antiviral drugs that block the assembly of subviral particles” PMID 31323705 ↗ Aug 2019 |
| Modality | Oligonucleotide (other) | “Nucleic acid polymers (NAPs; REP 2139-Ca and REP 2139-Mg)” PMID 31323705 ↗ Aug 2019 |
| Route | Intravenous | “REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.” NCT02646189 ↗ |